| Code | 42389 | ||||||||||
| MA number | EU/1/04/300/001 | ||||||||||
| Product Form: | con inf 1x4 ml/100 mg (liek.inj.skl.) | ||||||||||
| MA Status: | E - Valid centralised marketing authorisation | ||||||||||
| Type of procedure: | EU | ||||||||||
| MAH, country: | Roche Registration GmbH, Germany | ||||||||||
| Therapeutic Class: | 44 - CYTOSTATICA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 36 | ||||||||||
| Container: | glass vial | ||||||||||
| Route of admin.: | Intravenous use |
| Prescription Status: | Medicinal product subject to restricted medical prescription. |
| Legal basis: | Article 8(3) application |
| MA issued: | 12.01.2005 |
| SmPC + PL: |
European Medicines Agency's database
|
| Dokument: |
DHPC Avastin_NecrotisingFasciitis 15 5 2013.pdf
|
| Dokument: |
DHPC Avastin 30 4 2010.pdf
|
| Safety feature | Yes |
| Data update: | 11.01.2023 |
